0
First interlaboratory study in the world to replicate and validate high-profile studies on the cytotoxicity and inflammation induced by cigarette smoke and aerosol from electronic nicotine delivery systems (ENDS).
The Replica project team uses the most advanced tools and techniques and the most reliable methodologies to provide to the public up-to-date information on ENDS.
Testing the latest generation of alternative products to conventional cigarettes
To inform on the detrimental health effects of smoke, while accelerating efforts for the understanding, knowledge, and research capacity in the area of tobacco harm reduction and its role to end smoking, to better serve our worldwide communities.
Replica project coordinates a multi-center research network of academic and affiliated laboratories worldwide.
Since 2019 the team has been conducting inter-laboratory studies comparing the latest generation of alternative products (i.e. ECIGs and HTPs) to traditional tobacco cigarettes, and replicating results from in vitro research published on high impact journals to assess validity of the original work put under scrutiny.
CoEHAR Founder
CoEHAR Director and Project Leader
Co-project leader
Non-reproducible studies result in economic damage and prevents innovation, can harm individuals and erode public trust in science.
Replica Project addresses the need to standardize research through reproducibility and provides reliable scientific data on ENDS.
Replicate
high-profile in vitro studies testing ENDS
Assess validity of the original work put under scrutiny
Inform the scientific academia and the public of the progress
Contribute to improve local and international THR policies
The harmonization process required for all scientific documentation, materials, laboratories set up and experiments management is enriched by partner cultural diversity which prevents scientific bias or product stigma.
Commitment to pre-established design, methods and data analysis ensures value and credibility of scientific findings based on Reproducibility, while Multiple Methodology Comparison contributes to strengthen or debunk the original evidence.
Knowledge sharing of the leading center know-how with our international laboratory network is our priority. We have developed communication strategies of our technical expertise through multimedia methodologies.
Each project phase has been designed and managed following open science principles. Project result are shared in open access journals and repositories. Open education & training, inclusivity and open research characterize all our work.
The team replicated and validated the result of some of the most relevant studies in the field of tobacco harm reduction: overall, the data obtained independently in different laboratories clearly confirm the reduced cytotoxicity of ENDS products compared with smoking, the reduced impact of ENDS on vascular system and consequently the onset of atherosclerosis, and the reduced genotoxicity and mutagenicity of ENDS.
Ecig is 95% less harmful than traditional cigarette
